Skip navigation

Celgene Corp.

NAS : CELG
Pharmaceuticals
Summit NJ
2013 Revenue (US$ Millions)$6,494
2012 Revenue (US$ Millions)$5,507
Revenue Growth (%)17.93%
Net Income (US$ Millions)$1,450
Common Shares Outstanding (Millions)$410
Earnings Per Share (US$)$3.37
Price To Earnings Ratio170.77
Total Equity (US$ Millions)$5,590
Profit Margin (%)22.33%
Return On Equity (%)25.46%
Long Term Debt (US$ Millions)$4,197
Debt To Equity Ratio (%)0.75%
Market Capitalization (US$ Millions)$69,226
Total Assets (US$ Millions)$13,378
Return on Assets (%)12.36
Current Assets (US$ Millions)$7,551
Inventories (US$ Millions)$340
Current Liabilities (US$ Millions)$1,946
Cost of Goods Sold (US$ Millions)$340
Asset Turnover0.49
Inventory Turnover1.13
ExchangeNAS